Form 4: Theravance Biopharma Director Acquires Shares and Options

Susannah Gray, a director at Theravance Biopharma, acquired shares and options in the company on May 8, 2024.

Summary

• On May 8, 2024, Susannah Gray, a director of Theravance Biopharma, acquired 10,537 ordinary shares at $0 and disposed of 31,488 ordinary shares.
• Following these transactions, Gray beneficially owns 31,488 ordinary shares.
• Gray also acquired 23,576 share options with an exercise price of $9.49, exercisable from May 8, 2024, to May 7, 2034.
• These options vest monthly over 12 months, with any remaining unvested shares vesting on the date of the next annual meeting of the company's shareholders, provided the optionee remains in continuous service on such date.
• Following the transaction, Gray beneficially owns 23,576 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of options suggests confidence, but the disposal of shares tempers this view. Overall, it's a routine insider transaction.

Positives

• The acquisition of share options by a director could be seen as a positive signal, indicating confidence in the company's future performance.

Negatives

• The disposal of 31,488 ordinary shares by a director could be interpreted negatively, although the acquisition of shares and options on the same day may offset this concern.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency regarding the transactions of company insiders. These filings are closely watched by investors to gauge the sentiment and actions of those with the most knowledge of the company.

Stakeholder Impact

• The transactions may have a minor impact on shareholder sentiment, depending on how investors interpret the director's actions.

Key Dates